![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » RANBAXY RECEIVES TENTATIVE APPROVAL FOR GENERIC RISPERDAL
RANBAXY RECEIVES TENTATIVE APPROVAL FOR GENERIC RISPERDAL
August 7, 2006
Ranbaxy Laboratories, India's largest pharmaceutical company, has received tentative approval from the FDA to manufacture and market generic Risperdal (risperidone oral solution) 1 mg/mL.
Janssen's Risperdal is indicated for the treatment of schizophrenia. Total annual market sales for risperidone oral solution were $66 million for the year ending in March 2006.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct